Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

It is unclear whether differential roles of CD4(+) versus CD8(+) T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4(+) T-cell senescence (ie, the percentage of CD28(-)CD57(+) cells among CD4(+) T cells ) and CD4(+)/CD8(+) T-cell exhaustion (ie, the percentage of PD-1(+) cells among CD4(+)/CD8(+) T cells) decreased after ART. There were no changes in markers of CD8(+) T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4(+) and CD8(+) T cells may have differential roles in HIV pathogenesis.

[1]  O. Yang,et al.  Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. , 2015, The Journal of infectious diseases.

[2]  J. Currier,et al.  A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness , 2015, AIDS.

[3]  O. Yang,et al.  Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Lederman,et al.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.

[5]  R. Effros,et al.  T cell replicative senescence in human aging. , 2013, Current pharmaceutical design.

[6]  L. Kuller,et al.  Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals , 2012, PloS one.

[7]  R. Bosch,et al.  CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. , 2012, The Journal of infectious diseases.

[8]  P. Price,et al.  Immunosenescent CD57+CD4+ T-cells Accumulate and Contribute to Interferon-γ Responses in HIV Patients Responding Stably to ART , 2011, Disease markers.

[9]  F. Ceccherini‐Silberstein,et al.  Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. , 2011, Antiviral research.

[10]  E. Rosenberg,et al.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. , 2011, The Journal of infectious diseases.

[11]  Jeffrey N. Martin,et al.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. , 2011, The Journal of infectious diseases.

[12]  A. Sharrett,et al.  T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women , 2011, The Journal of infectious diseases.

[13]  A. Rebuzzi,et al.  Unusual CD4+CD28nullT Lymphocytes and Recurrence of Acute Coronary Events , 2007 .

[14]  A. Rebuzzi,et al.  Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. , 2007, Journal of the American College of Cardiology.

[15]  R. Effros,et al.  Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. , 2002, Clinical immunology.

[16]  N. Samani,et al.  Telomere shortening in atherosclerosis , 2001, The Lancet.